Objective: To examine the effects of vitamin C supplementation on the concentration of oxidation markers, in particular, circulating oxidized LDL (OxLDL) and on endothelial activation markers. Design: Randomized double-blind, placebo-controlled crossover trial. Setting: Belgian population of the city of Leuven. Subjects: A total of 34 healthy male smokers aged 26-73 y. Intervention: Smokers were randomly assigned to receive either vitamin C (250 mg twice daily) or placebo capsules, each to be taken for 4 weeks. After a 1-week washout period, participants then crossed over to the alternative capsules for further 4 weeks. Mean outcome measures: Markers of oxidation (bilirubin, uric acid, a-tocopherol, retinol, malondialdehyde, circulating Oxidized LDL (OxLDL)) and markers of endothelial activation (sICAM-1, sVCAM-1, vWF-antigen) were analysed. Results: Plasma ascorbate concentrations significantly increased from 46.6717.6 to 70.1721.2 mmol/l after a 4-week treatment with 500 mg vitamin C per day. The other plasma antioxidants concentrations, including bilirubin, uric acid, a-tocopherol and retinol, were similar in both treatment periods. Vitamin C did not change plasma malondialdehyde and circulating OxLDL compared with placebo (vitamin C 0.7370.25 mg/dl OxLDL; placebo 0.7270.21 mg/dl OxLDL). After vitamin C supplementation, neither sICAM-1 and sVCAM-1 levels nor the concentration of vWF-antigen significantly differed from placebo condition. Conclusions: Oral supplementation of vitamin C is not associated with changes in markers of oxidation or endothelial activation in healthy male smokers.
Introduction
Cigarette smoking represents a major risk factor for the development of atheroslerosis possibly due to the plethora of oxidants and free radicals in cigarette smoke (Davies, 1995; Diana, 1993; Pyror and Stone, 1993) . It has been hypothesized that free oxygen radicals act directly on the endothelial cells and induce oxidative modification of LDL in the subendothelial space of the vessel wall (Minotti & Aust, 1992) . Oxidized LDL (OxLDL) in turn may induce endothelial expression of adhesion molecules, like intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) (Penn & Chisolm, 1994; Holvoet, 1999) . Previous reports (Celermajer et al, 1993; Zeiher et al, 1995; Heitzer et al, 1996) have suggested that smoking induces endothelial dysfunction, which is regarded as an early event in atherogenesis.
Vitamin C is a strong reducing agent in plasma known to act as a major water-soluble antioxidant in vitro and in vivo (Frei, 1994) . It scavenges oxygen-derived free radicals and is thought to improve the integrity of the endothelium. One of the targets of vitamin C is probably oxidative modification of LDL. Vitamin C may protect LDL by scavenging free radicals in the aqueous phase and preserving the endogenous lipid-soluble antioxidants in LDL (Jialal et al, 1990; Frei, 1991; Retsky et al, 1993) . Smokers have lower plasma ascorbate concentrations than nonsmokers (Schectman et al, 1989; Walmsley et al, 1999) because of lower dietary intake (Morabia & Wynder, 1990) and depletion by smoking (Lykkesfeldt et al, 2000) .
Randomized trials in healthy smokers investigating these effects of vitamin C as the only supplement have previously been conducted. Vitamin C supplementation (500-2000 mg per day) has been shown to reduce the in vitro LDL oxidation susceptibility and plasma lipid peroxidation products thiobarbituric acid-reactive substrates (TBARS) (Harats et al, 1990 (Harats et al, , 1998 Fuller et al, 1996) . In addition, trials in which an infusion of 10-18 mg vitamin C/min (or total dose about 1000 mg) was given to chronic smokers provided promising results for improved endothelial-dependent vasodilation (Heitzer et al, 1996; Motoyama et al, 1997) . Weber et al (1996) showed that supplementation of smokers with 2000 mg vitamin C per day for 10 days normalized monocyte adhesion to endothelial cells.
Although the effects of vitamin C on LDL oxidation susceptibility as well as the short-term effects of vitamin C on endothelial function are well established in healthy smokers, effects on the levels of circulating OxLDL and of long-term supplementation on endothelial activation have not previously been examined. The present study was designed to investigate the effects of 4 weeks of vitamin C supplementation on the levels of oxidation markers, in particular, circulating OxLDL and malondialdehyde, and on the levels of endothelial activation markers (soluble ICAM-1 (sICAM-1), soluble VCAM-1 (sVCAM-1) and von Willebrand factor antigen (vWF-antigen)) in healthy smokers.
Subjects and methods

Subjects
A total of 42 healthy male smokers, aged between 25 and 75 y and smoking more than 10 cigarettes per day, were recruited through advertisements in local newspapers and by personally inviting subjects who had taken part in previous studies of our division. Of the 42 participants, eight subjects dropped out (no selective dropout) in the first 3 weeks of the study due to lack of motivation and scheduling conflicts. Thus, 34 smokers (mean (s.d.) age; 52712 y) have completed the study. All smokers were healthy as assessed by a medical questionnaire; did not adhere to a prescribed diet; did not use medication known to affect blood lipids or to have antioxidative properties (such as acetylsalicylic acid); were not diabetic as assessed by determining glucose in a urine sample and the medical questionnaire; were not obese (body mass index (BMI) o30 kg/m 2 ); and consumed less than 21 glasses per week of alcoholic drinks. Before the start of the study, the subjects completed a short questionnaire about their smoking habits, and a measurement of blood pressure, weight and height was performed. Table 1 shows the baseline characteristics of the 34 male smokers. Pack-years of smoking were calculated by multiplying the number of cigarettes smoked per day by the years of smoking divided by 20 (number of cigarettes per package). The mean BMI, systolic and diastolic blood pressure, pack-years of smoking and total cholesterol concentration were 25.172.9 kg/m 2 , 129714 and 8177 mmHg, 42729 and 213740 mg/dl, respectively. Most of the participants had a low or intermediate educational level.
Study design
The study design used was a randomized, double-blind, placebo-controlled crossover trial. This study was approved by the Medical Ethics Committee of the University of Leuven. All participants gave their written informed consent for participation prior to the start of the study. The smokers were randomly assigned to receive either vitamin C capsules (250 mg twice daily) or placebo capsules, each to be taken for 4 weeks. After a 1-week washout period, participants then crossed over to the alternative capsules for a further 4 weeks. The dose of 500 mg was ingested in two portions because the bioavailability was found to be incomplete for doses over 200 mg of vitamin C (Levine et al, 1996) . The placebo capsules contained only lactose. None of the subjects had a history of lactose intolerance. Subjects were instructed to take both capsules between the meals to reduce the possibility of influencing iron status. All capsules were Blood collection Blood samples were taken at the start of the study, and at the end of week 3 and week 4 of the vitamin C and placebo period. These five blood samples were collected between 8 and 10 am after an overnight fast (since 22 h) and after abstinence from smoking (same day) and drinking alcohol (day before). The measurements of the selected markers in the first blood sample at the start of the study were used to characterize the study population, while the measurements of weeks 3 and 4 of each capsule period were averaged to test the effect of vitamin C. All venipunctures of each subject were performed at the same hour of the day. About 20 ml blood was collected into four different tubes. The K-EDTA tube (4 ml) was immediately centrifuged to separate plasma for the determination of ascorbate, a-tocopherol, retinol and malondialdehyde. For the analysis of ascorbate, the plasma samples were treated with 5% metaphosphoric acid (800 ml metaphosphoric acid, 200 ml plasma), and this sample was centrifuged at 1200 Â g and the supernatant fluid stored at -801C. The lithium-heparin tube (5 ml) and CTAD tube (5 ml) (CTAD, Diatubes of Becton Dickinson/Diagnostica Stago) were kept at room temperature and centrifuged at 1200 Â g (10 min, room temperature) within 1 h after collection. Plasma from CTAD tubes was used for analysing oxidized LDL and von Willebrand factor antigen. Extra vitamin E (20 mM) and butylated hydroxytoluene (10 mM) as antioxidants were added to the plasma aliquots to prevent the in vitro oxidation of LDL cholesterol. Finally, 5 ml blood was drawn in a 5 ml clotting-tube to obtain serum after centrifugation at 1200 Â g (10 min, room temperature) 1 h after venipuncture. All samples were divided into aliquots and stored at À801C before analysis and thawed at room temperature for analysis.
Laboratory analysis
Plasma ascorbate was measured by high-performance liquid chromatography (HPLC) isocratic delivery using a reversephase column Prevail C18 (Alltech, Deerfield, IL, USA) with 2 mM KCl mobile phase and electrochemical detection at 1000 mV (Washko et al, 1992) . Plasma a-tocopherol and retinol were determined by HPLC (Shimadzu, Kyoto, Japan) with a reversed-phase C18 column LiChrospher RP C18 (Alltech, Deerfield, IL, USA) with 100% methanol mobile phase and detection at 292 and 325 nm, respectively (CayeVaugien et al, 1990) . Plasma malondialdehyde was analysed by HPLC using reverse LiChrospher RP C18 (Alltech, Deerfield, IL, USA) methanol/KH 2 PO 4 10 mM (40/60 v/v) as mobile phase and detection at 532 nm (Nielsen et al, 1997) .
Lithium-heparin plasma was analysed for the concentration of iron, ferritin, total cholesterol, HDL cholesterol, triglycerides, total bilirubin and uric acid. Iron was measured spectrometrically as ferrozine-iron complex (Roche, Basel, Switzerland). Ferritin was analysed by Microparticle Enzyme Immunoassay (MEIA) Technology using AxSYM Ferritin Reagents (Abbott Laboratories, Abbott Park, IL, USA). Total cholesterol (CHOD-PAP method, Roche, Basel, Switzerland), HDL cholesterol (CHOD-PAP method after incubation with a-cyclodextrinsulphate; Roche, Basel, Switzerland) and triglycerides (GPO-PAP method; Roche Diagnostics, Basel, Switzerland) were analysed enzymatically on a Hitachi 747 analyser (Roche Diagnostics, Basel, Switzerland). LDL cholesterol values were calculated using the Friedewald equation (Friedewald et al, 1972) . Total bilirubin was measured by 2,5 dichlorophenyl diazonium (DPD) method on Hitachi 917 and Hitachi 747 analysers (Roche Diagnostics, Basel, Switzerland). Uric acid was measured with an enzyme-linked colorimetric assay (Roche, Basel, Switzerland).
Plasma levels of circulating OxLDL were quantitated with a monoclonal antibody (4E6)-based competition ELISA. The monoclonal antibody 4E6 is directed against a conformational epitope in the apolipoprotein B-100 moiety of LDL that is generated as a consequence of substitution lysine residues of apolipoprotein B-100 with aldehydes. Substituting aldehydes can be produced by peroxidation of lipids of LDL, resulting in the generation of OxLDL (Holvoet et al, 1994; . Plasma von Willebrand factor antigen (vWFantigen) concentrations were measured with a 2-step enzyme immunoassay method with final fluorescent detection (ELFA Enzyme Linked Fluorescent Assay) (bioMérieux sa, Lyon, France). The intensity of the fluorescence is proportional to the concentration of antigen present in the sample. The VIDAS vWF test is calibrated against the WHO International Standard (No. 91/666), and the concentrations are expressed as % (and 1 IU/ml ¼ 100%).
Serum levels of sICAM-1 and sVCAM-1 were estimated with a sandwich enzyme immunoassay (ELISA kits from R&D Systems (Europe) Ltd., 4-10 The Quadrant, Abingdon OX14 3YS, UK). A monoclonal antibody specific for sICAM-1 and sVCAM-1 has been precoated onto a microplate.
All samples of each subject were analysed within one run to avoid inter-assay variation. In addition, serum and plasma aliquots were combined in a pool sample. This pool sample was analysed twice in each run to estimate intra-assay variation. The intra-assay coefficient of variations (CV, %) of variables were 6.0% for ascorbate, 4.8% for a-tocopherol, 4.1% for retinol, 9.0% for malondialdehyde, 1.3% for iron, 4.0% for ferritin, 1.9% for total bilirubin, 1.7% for uric acid, 1.0% for total cholesterol, 1.9% for HDL cholesterol, 1.8% for triglycerides, 7.6% for circulating OxLDL, 4.6% for vWF-antigen, 3.6% for sICAM-1 and 4.8% for sVCAM-1. The performance of all samples was blinded to treatment periods.
Dietary assessment
A 3-day food record using household measures was used to assess diet in the last week of each period. The records were explained to the volunteers by a dietitian and checked when handed in. The intake of nutrients, including dietary vitamin C and iron, was estimated using the BECEL computer program (Brussels, Belgium) for the calculation of nutrient intake. The data bank of BECEL is based on the Belgian and Dutch food composition tables. None of the participants took any other antioxidant supplement.
Sample size calculation and statistical analysis
The primary outcome of the crossover study was the change in OxLDL between the vitamin C and placebo period. Based on the within-subject standard deviation of OxLDL between three repeated measurements in healthy men (s.d. of 0.13 mg/dl) (Van Hoydonck et al, 2003) , we calculated the sample size. In all, 21 individuals would be needed to detect a 10% difference between the means of OxLDL in a crossover study at 5% significance level with 80% power. We have chosen to recruit 40 smoking men.
Data were analysed using the General Linear Models (GLM) procedure of the Statistical Analyses System (Version 8.1., SAS Institute, Inc., Cary, NC, USA) with treatment (vitamin C or placebo), period and treatment-period interaction as independent variables. The average values of the markers of vascular integrity of weeks 3 and 4 for each capsule period were calculated to have a more precise estimate of the value at the end of each period. This value was taken as a dependent variable. The interaction term between treatment and period was calculated to assess the presence of carryover effects of the vitamin C/placebo treatments. A P-value of less than 0.05 was regarded as statistically significant and all P-values were based on twosided tests.
Results
Compliance
The compliance of the subjects to the protocol was satisfactory, as judged from the returned empty strips of capsules. Of the total 1904 capsules of 250 mg vitamin C or placebo twice daily provided per period, 96% was returned empty with no difference between periods.
Lipids, lipoproteins and oxidative and endothelial markers Table 2 shows the concentrations of lipids, lipoproteins and oxidative and endothelial markers at the end of each treatment period. The total cholesterol concentration as well as LDL-, HDL-cholesterol and triglycerides did not differ between the two treatment periods. There was a significant increase in plasma ascorbate concentration after 4 weeks of treatment with 500 mg vitamin per day compared with placebo capsules (70.1721.2 vs 46.67 17.6 mmol/l, respectively; Po0.0001). A significant treatment-and-period interaction was detected in plasma ascorbate concentration indicating the presence of carryover effects of the vitamin C treatment. The plasma antioxidants concentrations, including bilirubin, uric acid, a-tocopherol and retinol, were similar (P ¼ 0.94, 0.58, 0.98, and 0.94, respectively). The concentration of malondialdehyde and circulating OxLDL remained unchanged. Neither sICAM-1 and sVCAM-1 levels nor the concentration of vWF-antigen of male smokers significantly differed between the treatment periods. The results did not change when the order of the treatments was taken into account (results not shown).
Dietary intake
Diet composition, as analysed from a 3-day record, in each treatment period is shown in Table 3 . The reported energy intake was slightly different between the treatment periods (11.172.4 MJ in control and 10.573.1 MJ in vitamin C period, P ¼ 0.37). During the vitamin C period, smokers consumed slightly less fruit (À9 g per day) and vegetables (À30 g per day), had lower daily vitamin C (4.4 mg per day) and iron intake (À1.8 mg per day) and took a higher percent of energy from polyunsaturated fatty acids (0.4 En%) compared to the placebo period. None of the differences in dietary intake between two supplemental periods were statistically significant. 
Discussion
This randomized, double-blind, placebo-controlled crossover trial did not provide evidence that extra vitamin C given to smokers affects the levels of circulating OxLDL and endothelial markers, including, sICAM-1, sVCAM-1 and vWFantigen, despite a considerable increase in plasma ascorbate concentrations.
A number of 4-week supplementation studies in healthy smokers have indicated that vitamin C effectively reduced the in vitro susceptibility of LDL for oxidation (Fuller et al, 1996; Harats et al, 1998) and the concentration of plasma lipid peroxidation products such as conjugated dienes and TBARS (Harats et al, 1990 (Harats et al, , 1998 Fuller et al, 1996) . A possible mechanism explaining why vitamin C might reduce the oxidative modification of LDL is by scavenging aqueous free radicals before they can attack and oxidize LDL. LDL oxidation susceptibility possibly is a short-term marker of this process, whereas circulating OxLDL probably is not, rather being a marker of processes taking place within the lipophilic environment of the arterial wall. In this case, 4 weeks of supplementation might be too short to influence the concentration of circulating oxLDL leaking back from the subendothelial space to the blood.
A different proposed mechanism for effects of vitamin C on LDL oxidation is through regeneration of a-tocopherol from the a-tocopherol radical, on the outside of the LDL particle (Niki, 1991) . This way, vitamin C may function as an antioxidant even when the oxidation proceeds in the lipid domain, including the arterial wall. Vitamin C supplementation did not increase plasma a-tocopherol concentration, which is in agreement with previous supplementation studies in smokers (Harats et al, 1990; Fuller et al, 1996; Diaz et al, 1997; Neuzil et al, 1997) . However, even then, the prooxidant/antioxidant balance in arterial tissue may be favourably influenced and protect LDL against oxidation (Mezzitti et al, 1995) .
In the Health ABC cohort, the strongest independent predictors of levels of circulating OxLDL were hypercholesterolaemia, followed by dyslipidaemia and inflammation (CRP). Similar associations were observed in persons with and without CHD (Holvoet et al, 2003) . Short-term interventions reported to lower OxLDL concentrations significantly are treatment with artorvastatin and weight reduction, whereas a combination of antioxidants (500 IU vitamin E, 100 mg vitamin C, 5 mg b-carotene, 100 mg selenium and 15 mg zinc) slightly, but not significantly, lowered OxLDL (Mertens, 2002) . Treatment for 4 weeks with artorvastatin induced a 41% decrease in LDL cholesterol and 40% decrease in circulating OxLDL concentrations and 2 weeks weight reduction with Orlistat resulted in significant decreased LDL cholesterol (À7%) and OxLDL concentrations (À12%) (Mertens, 2002) . The reported effects on OxLDL thus strongly correlated with changes in LDL cholesterol. Whether OxLDL concentrations are also modifiable by other dietary or lifestyle factors, independent of changes in LDL cholesterol, remains questionable.
Supplementation with vitamin C did not affect the levels of sICAM-1, sVCAM-1 and vWF-antigen in our study. The concentrations of sICAM-1 and sVCAM-1 in our smokers' population during the placebo treatment were slightly higher than the concentrations in nonsmoking control subjects reported in the study of Blann and coworkers; 297769 vs 263777 ng/ml for sICAM-1 and 7657152 vs 6017153 ng/ml for sVCAM-1 (Blann et al, 1998) . Endothelial activation (as measured by adhesion molecules) and impaired endothelium-dependent vasodilation (forearm blood flow or brachial artery flow-mediated dilation) are regarded as the main indicators of impaired endothelial function. Recent publications Tousoulis et al, 2003) reported that a combination of vitamin C (2 g/day) and vitamin E (800 IU/day) given for 4 weeks significantly decreases sICAM-1 (À14%), sVCAM-1 (À14%) and vWF (À21%) concentrations in healthy smokers, whereas vitamin C alone (2 g/day) did not change adhesion molecules concentrations after 4 weeks of supplementation compared with baseline concentrations. The investigators however, did not compare the changes on the different treatments vs the control condition. Especially for sICAM-1, differences in baseline levels between groups largely explained the results and in our opinion this study did not convincingly show the effects or absence of effects of vitamin C, E or combinations on adhesion molecules. Another investigator group (Rayment et al, 2003) reported in nonsmokers with low plasma vitamin C (o50 mM) significant ICAM-1 mRNA and serum ICAM reductions (À7%) after 6 weeks vitamin C supplementation with 250 mg/day. In the present crossover trial, we separated the smokers into those having low (o45 mM) and those having high initial plasma vitamin C concentrations, and no difference was found for the different markers between the vitamin C and the control condition. We, however, do not exclude that the baseline ascorbate level is an important predictor for changes in endothelial function by vitamin C and must be taken into account in further research. Several studies reported beneficial acute effects of high doses of vitamin C, administered either orally or by intraarterial infusion, on other measures of endothelial function in smokers. Supplementation of smokers with 2000 mg vitamin C per day for 10 days significantly reduced monocyte adhesion to cultured endothelial cells (Weber et al, 1996) . Heitzer et al (1996) and Motoyama et al (1997) observed increased vasodilation in smokers given an infusion of 10-18 mg vitamin C/min (or a total dose of about 1000 mg). The longer-term effects of vitamin C on endothelial function have been studied in patients with coronary artery disease (Gocke et al, 1999) . The investigators found that both a single dose of 2000 mg vitamin C and a longterm treatment of 500 mg/day vitamin C for 4 weeks improved flow-mediated dilatation (FMD) in patients with coronary artery disease, particularly in subjects with impaired baseline FMD. Although they did not demonstrate any effects of vitamin C on circulating products of lipid peroxidation (plasma 8-epi-prostaglandin F 2a ) or protein oxidation products (urine dityrosine and o-tyrosine) or intracellular glutathione, the authors speculated that vitamin C improved vasodilation by enhancing intracellular redox state or by some other undetermined mechanism.
We have chosen a daily dose of 500 mg in two portions, because in a study of Levine et al (1996) complete plasma saturation (plateau-steady state) occurred at 1000 mg at the expense of decreased bioavailability and increased urinary excretion of urate and oxalate. Further, the bioavailability was found to be incomplete for doses over 200 mg of vitamin C (Levine et al, 1996) . The previous studies in healthy smokers on LDL susceptibility for oxidation applied daily doses of 500 mg (Harats et al, 1998) , 1000 mg (Harats et al, 1990; Fuller et al, 1996) and 1500 mg (Harats et al, 1990) vitamin C, which resulted in 2.0-2.3-fold (Harats et al, 1990) , 3.8-fold (Harats et al, 1998) to 3.9-fold (Fuller et al, 1996) increase in plasma ascorbate levels. In our study, the increase in mean plasma ascorbate was similar to the study of Harats et al (1990) . The stronger increase in the other studies (Fuller et al, 1996; Harats et al, 1998 ) may partly be due to a low vitamin C diet and related low plasma ascorbate concentrations. Indeed, the baseline plasma ascorbate concentration in the present study (45720 mmol/l) was higher than that in the above-mentioned studies. This may partly explain the absence of an effect in the present study.
Some methodological problems such as selection bias, dropout, carryover effect might have influenced the internal validity of our study. Our study population may constitute a healthy subpopulation of the source population of smokers. This is reflected by BMI (25 kg/m 2 ), blood pressure (129/ 81 mmHg), lipid and lipoprotein concentrations (within the normal range for healthy subjects), plasma ascorbate (45 mmol/l) and dietary intake of vitamin C (76 mg per day). The rather healthy lifestyle of our smokers may limit the generalizability of the reported findings. We do not think with regard to baseline characteristics of the subjects that the dropout that occurred during the first 3 weeks of the study can explain our null finding. It may be explained to some extent by the presence of carryover effects of vitamin C treatment in our study (detected in plasma ascorbate concentration), which may have reduced the power of the study.
In conclusion, oral supplementation of 500 mg/day vitamin C for 4 weeks is not associated with changes in circulating OxLDL or endothelial activation markers in healthy male smokers. However, effects of higher dosages, longer supplementation duration or at lower background plasma ascorbate concentrations cannot be excluded.
